ClinicalTrials.gg
Not yet recruitingNCT04980703Updated May 14, 2025

Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial

An interventional study of Grain moxibustion and Sham grain moxibustion in Sleep Initiation and Maintenance Disorders, sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian. Not yet recruiting at 2 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Shanghai Institute of Acupuncture, Moxibustion and Meridian · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China — 82 open to participants now, 88 under way, 2 of them phase 3. Sleep Initiation and Maintenance Disorders · China.

Planned enrollment
74th of 162
102 · median 88
Started
2027
the only one that year
No phase
123 of 198
56 open now
Primary completion
2029-07
later than 83 of 87 live
Registered
42nd of 198
by date

Among the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, this one is the 74th largest by planned enrollment of the 162 interventional ones that give a count, is the only one that started in 2027, is one of 123 with no phase, reaches primary completion later than 83 of the 87 other live ones, and was the 42nd registered.

Sleep Initiation and Maintenance Disorders

2,738 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 735 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

82 of the 198 studies in Sleep Initiation and Maintenance Disorders with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 394 Sleep Initiation and Maintenance Disorders studies recruiting now, 156 (40%) set no upper age limit and 208 (53%) stop at 75 or younger; 61 take children under 18; 112 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 198 studies in Sleep Initiation and Maintenance Disorders with a site in China, or all of them as a file.
02

Study summary

This trial intends to observe the clinical efficacy and safety of grain moxibustion at Baihui(GV20), Xinshu(BL15) and Pishu(BL20) in the treatment of insomnia.

Read the detailed description

Insomnia is one of the most common sleep disorders. The main symptoms are difficulty in falling asleep, decreased sleep quality and sleep time, and affect the normal work, study and life during the day.

Acupuncture has a good clinical effect on insomnia, but most of the treatment methods are acupuncture or electroacupuncture. Moxibustion therapy, as one of the main components of the therapy, has the advantages of simple operation, wide acceptance, which is suitable for a wide range of promotion and application.At present, the trials of moxibustion in the treatment of insomnia mainly focus on mild moxibustion. The number of studies is small, and the research is designed insufficiently, so it is difficult to draw a positive conclusion, and needs to be further confirmed by rigorous designed experiments. In addition, grain moxibustion, which is widely used in clinic, has the advantages of more convenient operation, short treatment time and strong permeability. However, its efficacy and safety in the treatment of insomnia are still unclear, so it is necessary to carry out a randomized controlled trial to confirm it.

One hundred and two eligible patients will be randomly assigned to one of 3 groups: grain moxibustion group, sham grain moxibustion group and wait-list control group. Treatment will be given 3 times per week for 4 weeks. The primary outcome is the Pittsburgh Sleep Quality Index (PSQI). The secondary outcomes are changes of PSQI scores from baseline to 8 week follow-up, sleep monitoring of bracelet, Athens Insomnia Scale(AIS), Generalized Anxiety Disorder Scale-7 (GAD-7), Patient Health Questionnaire-9 (PHQ-9) and recurrence observation during the follow-up period. Daily dose of patients' estazolam will be recorded in the dairy. All adverse effects will be assessed by the Treatment Emergent Symptom Scale (TESS). Outcomes will be evaluated at baseline, 4 weeks post-treatment, as well as at 8 week and 12 week follow-up.

This trial intends to observe the clinical efficacy and safety of grain moxibustion at Baihui(GV20), Xinshu(BL15) and Pishu(BL20) in the treatment of insomnia, which will provide an experimental basis for the treatment of insomnia with grain moxibustion and lay the foundation for the promotion and application of moxibustion in the future.

03

Conditions studied

  • Sleep Initiation and Maintenance Disorders

Keywords

  • moxibustion
  • insomnia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the diagnostic criteria of insomnia;
  2. TCM syndrome differentiation belongs to deficiency of both heart and spleen;
  3. Male or female participants aged 18-75;
  4. Participants whose PSQI score is 5-15;
  5. The course of disease is more than 3 months;
  6. Participants who voluntarily agree with the investigation and sign a written form for the clinical trial.

Exclusion criteria

Exclusion Criteria:

  1. Participants with mental retardation;
  2. Participants with serious cardiovascular diseases, liver, kidney and hematopoietic system diseases;
  3. Insomnia is caused by nervous system diseases (such as stroke, Parkinson's disease) or mental disorders (including depression or anxiety);
  4. Female participants who is pregnant or lactating;
  5. Participants with diabetes and sensory dysfunction.
  6. Participants with skin diseases of acupoints;
  7. Taking sedative hypnotics (including barbiturates, benzodiazepines, tranquilizers, diphenylmethane, etc) and other insomnia related drugs within 2 weeks before the trial;
  8. Participants with dependence on sleeping drugs;
  9. Participants suffering from malignant tumor, sequelae of severe cerebral apoplexy, organ failure and other major diseases that affect insomnia and therapeutic effect.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Grain moxibustion

    Grain moxibustion +standard care

    Device: Grain moxibustion

  • Sham comparator
    Sham grain moxibustion

    Sham grain moxibustion +standard care

    Device: Sham grain moxibustion

  • Other
    Wait-list control

    Standard care

    Other: Standard care

Interventions

  • DeviceGrain moxibustion

    Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the patient feels burning or a little pain, put out moxa with gauze and keep for 10 seconds, so as to ensure enough heat to be penetrated into the acupoint. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).

  • DeviceSham grain moxibustion

    Take Baihui(GV20), apply vaseline on the acupoint, knead moxa villi into grain size, put it on GV20, and ignite it with incense. When the moxa burns to half (the patient hasn't feel hot or feel a little hot), take the moxa away with tweezers. There are 3 cones for the first six times and 5 cones for the last six times . After the treatment of GV20, the patient will be in prone position. Select bilateral Xinshu(BL15) and Pishu(BL20) and operate the same as that of GV20. 3 times a week, 12 times in all. During the trial, patients with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.).

  • OtherStandard care

    Participants in the wait-list control with severe sleep disorders will be allowed to take the sedative-hypnotic drug eszopiclone 0.5-2mg orally (Sinopharm approval H31021534, Shanghai Shangyao Xinyi Pharmaceutical Co., Ltd.). And after waiting for 12 weeks, these patients will be treated with the same grain moxibustion as the grain moxibustion group.

06

What researchers measure

Primary outcomes

  1. Changes of Pittsburgh Sleep Quality Index (PSQI)

    The Pittsburgh Sleep Quality Index (PSQI) is a widely-used questionnaire to assess one's sleep disorders over one month. It is comprised of 19 self-rated items and 5 other-rated items. The scores include the following indicators: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of medication, and daytime dysfunction. Each indicator is rated from 0 to 3. The accumulated scores of the seven indicators constitute the total score of PSQI (0-21). The higher score indicates the worse sleep quality and severer sleep disorders. The investigators set the changes of PSQI scores between baseline to week 4 as the primary outcome, to evaluate the effectiveness of acupuncture for depression related insomnia.

    Time frame: Baseline and week 4

Secondary outcomes

  1. Changes of PSQI scores

    As is mentioned above, PSQI is a widely-used questionnaire to assess one's sleep disorders over one month. In order to assess the effects of acupuncture on patients' sleep quality during the intervention period, and to assess the durative effects of acupuncture after the intervention ends, the investigators set the changes of PSQI scores between baseline to week 8 and week 12 as the secondary outcome.

    Time frame: Baseline and week 12

  2. Sleep monitoring of bracelet

    Xiaomi Bracelet 3(XMSH05HM)will be worn on the wrist of the participants, recording the sleep time at night, deep sleep time, light sleep time, awake time, time to fall asleep last night and time to wake up this morning.

    Time frame: Week 12

  3. Changes of Athens Insomnia Scale(AIS)

    Using the Athens Insomnia Scale to test the subjective sleep quality of patients. It is comprised of 8 items. The range were from 0-3. Total score \< 4 means sleep well; total score =4-6 means suspicious of insomnia; total score \> 6 means insomnia. The changes of AIS scores between baseline to week 4, week 8 and week 12 are the secondary outcome.

    Time frame: Baseline and week 12

  4. Changes of Generalized Anxiety Disorder Scale-7(GAD-7)

    Changes in anxiety will be measured using the Generalized Anxiety Disorder Scale (GAD-7), which contains 7 items with total scores ranging from 0 to 21. Scores of 5, 10, and 15 are cut-offs for mild, moderate, and severe anxiety, respectively. An add-on item assessing the patient's global impression of symptom-related impairment helps researchers understand the extent to which anxiety interferes in daily life. The GAD-7 has factorial validity for the diagnosis of general anxiety disorder and is sensitive to change. The changes of GAD-7 scores between baseline to week 4, week 8 and week 12 are the secondary outcome.

    Time frame: Baseline and week 12

  5. Changes of Patient Health Questionnaire-9 (PHQ-9)

    Changes in depressive symptoms will be measured using the 9-item Patient Health Questionnaire-9 (PHQ-9) to assess depressive symptoms. With total scores ranging from 0 to 27, scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively. The PHQ-9 has factorial validity for the diagnosis of major depressive disorder. The changes of PHQ-9 scores between baseline to week 4, week 8 and week 12 are the secondary outcome.

    Time frame: Baseline and week 12

  6. Recurrence observation during the follow-up period

    In case of relapse (PSQI score increase rate \> 50% or need to adjust drugs to control the disease) or serious adverse reactions during the follow-up period, the time from the beginning to the end of treatment , the specific medication plan and the state of illness during the follow-up period will be recorded. The recurrence rate and average recurrence time during the follow-up period will be calculated according to the number of recurrence within week 4 to week 12 follow-up in each group.

    Time frame: Week 12

  7. Dose dairy

    Compare the use rate and dosage of estazolam during treatment and follow-up.

    Time frame: 12 weeks

Other outcomes

  1. Blind evaluation

    The participants will be asked to predict whether they were treated by grain moxibustion or sham grain moxibustion according to their self feelings.

    Time frame: Week 4

  2. Abnormalities after the moxibustion

    Abnormalities after the moxibustion are skin scald, blistering or other discomfort caused by the moxibustion. Doctors will always have a burn ointment to prevent burns. If the patient gets a blister, the doctor will deal with it in time and inform the patient of the follow-up protective measures.

    Time frame: Week 4

07

Study locations

2 sites
  • Shanghai Institute of Acupuncture, Moxibustion and Meridian
    Shanghai, Shanghai 200030, China
  • Shanghai Institute of Acupuncture, Moxibustion and Meridian
    Shanghai, Shanghai, China
08

References and documents

Individual participant data

Plan to share: Yes — Individual Participant Data (IPD) will be maintained by the principal investigator. Other investigators may consult with the principal investigator.

Supporting information: Study protocol

Time frame: The protocol will be published online and is expected to be available in one to two years.

Access criteria: Open up online for everyone.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2027; primary completion for Jul 2029, 24 months later.

Of 1,219 non-industry interventional studies with no phase under Sleep Initiation and Maintenance Disorders, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 35. This study's planned 24 months is above that.

Counting every sponsor, half of 1,297 studies reached it within 15 months; a quarter within 6 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2021
First posted
Jul 28, 2021
StartEst.
Jul 1, 2027
Primary completionEst.
Jul 31, 2029
CompletionEst.
Jul 31, 2029
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04980703
Lead sponsor
Shanghai Institute of Acupuncture, Moxibustion and Meridian
Responsible party
Sponsor
First posted
Jul 28, 2021
Start date
Jul 1, 2027 (estimated)
Primary completion
Jul 31, 2029 (estimated)
Completion
Jul 31, 2029 (estimated)
Last update
May 14, 2025

Study contacts

Chunhui Bao, PhD, MD
Contact
baochunhui789@126.com
+8664395973
Huangan Wu, PhD, MD
study chair · Shanghai Institute of Acupuncture and Meridian

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion